Tirzepatide Ads Banned on Meta: Reversal Strategies

Tirzepatide Ads Face a Double Classification Problem

Tirzepatide is the active ingredient in Mounjaro and Zepbound. It is unique among GLP-1 compounds because it also acts on GIP receptors, which gives it a dual mechanism of action. Meta's automated enforcement sees two red flags: a prescription pharmaceutical and a weight loss drug. This double classification makes tirzepatide ads the hardest to keep live on the platform.

We have worked with compounding pharmacies that had entire ad accounts disabled after launching tirzepatide campaigns. In every case, the core issue was the same: Meta's policy engines classified the ads as promoting a prescription weight loss drug, and no amount of disclaimers in the fine print changed that classification because the engine never read the fine print.

Why Tirzepatide Gets Flagged Faster Than Other GLP-1s

Meta's ad review system uses a layered approach. The first layer is keyword-based filtering. The second layer is image recognition. The third layer, which happens only after an appeal, is human review. Tirzepatide ads rarely survive the first layer because the combination of weight loss language and a recognizable pharmaceutical name triggers multiple policy categories simultaneously.

Compounding this problem is the fact that tirzepatide is still under patent as Mounjaro and Zepbound. Branded GLP-1 drugs are among the most aggressively enforced pharmaceutical categories on Meta. Any ad that mentions tirzepatide, Mounjaro, or Zepbound, even in a disclaimer, runs a near-certain risk of rejection.

The Specific Triggers

The drug name anywhere in the creative. Tirzepatide, Mounjaro, Zepbound. Any of these in the ad copy, image, or landing page URL slug triggers automatic rejection. Even "compounded tirzepatide" gets flagged because the system does not parse the modifier, only the root term.

Weight loss outcome language. Any mention of pounds lost, body transformation, A1C reduction, or before-and-after framing triggers Meta's personal attributes policy. This policy prohibits ads that reference a person's physical condition or imply a negative self-perception. Tirzepatide ads almost always violate this because the primary use case is weight loss.

Dual GLP-1/GIP claims. Explaining tirzepatide's mechanism of action in the ad is a common mistake. Mentioning that it is a GLP-1 and GIP receptor agonist signals to Meta's classifiers that the ad is making a medical claim about a prescription drug. Keep the mechanism language on the landing page, never in the ad.

Comparative efficacy statements. Statements like "more effective than semaglutide" or "superior weight loss results" are pharmaceutical efficacy claims. Meta prohibits these for prescription drug categories. Even if the claim is supported by clinical data, Meta's policy does not permit it in advertising.

FDA 503A and 503B for Tirzepatide Advertising

The same FDA compounding frameworks apply, but tirzepatide adds complexity because it is a dual-agonist under active patent protection. Pharmacies compounding tirzepatide under FDA 503A must ensure their advertising frames the service as individualized compounding for a specific patient following a prescription, with no implication of off-the-shelf availability.

Under FDA 503B, outsourcing facilities must add language about sterility assurance, batch testing, and cGMP compliance. The BAV appeal pathway on Meta is especially important for 503B facilities because the larger scale of operation triggers additional scrutiny. Submit your FDA establishment registration, state board license, and quality documentation at the time of BAV application.

Our Tirzepatide Approval Strategy

Remove every drug name from every surface. Use "GLP-1/GIP metabolic therapy consultation" or "compounded injectable weight management" in place of tirzepatide, Mounjaro, or Zepbound. This includes the ad copy, the display URL, the image alt text, and the landing page h1. Nothing recognizable as a drug name can appear anywhere the review system scans.

Eliminate all weight loss language from ads. Do not say "lose weight," "drop pounds," or reference any numeric outcome. Instead, talk about metabolic health, body composition optimization, and medically supervised treatment programs. The ads must read as healthcare service ads, not weight loss ads.

Separate the mechanism explanation from the ad. Your landing page can explain how GLP-1 and GIP receptor agonists work. Your ads cannot. Ads promote the consultation. The landing page educates. Keep them in different lanes.

Submit BAV documentation before your first ad. Include your pharmacy license, DEA registration, FDA establishment registration if 503B, liability insurance certificate, and a letter from the pharmacist-in-charge explaining the compounding framework. Pre-verified accounts get fewer automated flags.

Tirzepatide Ads Approved After 8 Days of Rejections

We took over a tirzepatide campaign for a 503A pharmacy that had 12 ads banned in a single week. Every ad featured weight loss statistics, referenced Mounjaro as a comparison point, and linked to a landing page that displayed pricing. The pharmacy was about to give up on paid advertising entirely.

We rebuilt the campaign from scratch. New ad copy promoting "metabolic health consultations" with no drug names. New landing page structured as a medical evaluation flow with FDA 503A disclaimers and no pricing displayed until after a consultation booking. New BAV submission with full pharmacy documentation.

Eight days after the rebuild, all ads were approved and the account returned to full standing. The pharmacy has since scaled to six active campaigns across Meta, all using the same drug-name-free, consultation-first framework. Zero rejections in five months.

The BAV Advantage for Tirzepatide Advertisers

One thing we learned: completing BAV before submitting your first ad changes the review pathway. Verified business accounts get routed through a different queue that includes human review earlier in the process. Unverified accounts get automated rejection first and human review only on appeal. For tirzepatide, where the automated rejection rate is near 100 percent, BAV is the difference between a one-week approval and a three-month battle.